In terms of tumor control mechanisms, both HIS- and patient-derived CD4 CTLs exhibit specific HLA-II dependent tumor cell killing ex vivo, accompanied by the release of cytotoxic granules and proinflammatory cytokines25,26. The gene discussed is CD4; the disease is neoplasm.